HLA haplotype-mismatched transplantations for AML with and without NK cell alloreactivity in the GVH direction according to patient series
| NK cell alloreactivity in GvH direction . | 1993–20014 . | 2002–2006 . | 1993–2006 . | |||
|---|---|---|---|---|---|---|
| No n = 37 . | Yes n = 20 . | No n = 24 . | Yes n = 31 . | No n = 61 . | Yes n = 51 . | |
| Status of disease at transplantation, n (%) | ||||||
| Bad-risk first and second CR | 7/37* (18.9) | 3/20* (15) | 19/24* (79.1) | 23/31* (74.2) | 26/61* (42.6) | 26/51* (51) |
| Myelodysplasia | 2/7 (28.6) | 1/3 (33.3) | 2/19 (10.5) | 5/23 (21.7) | 4/26 (15.5) | 6/26 (23) |
| Unfavorable cytogenetics | 2/7 (28.6) | 0/3 (0) | 4/19 (21.1) | 10/23 (43.5) | 6/26 (23) | 10/26 (38.5) |
| First-line induction therapy or autologous transplant failure | 3/7 (42.8) | 2/3 (66.7) | 13/19 (68.4) | 8/23 (34.8) | 16/26 (61.5) | 10/26 (38.5) |
| More than second complete remission | 4/37* (10.8) | 3/20* (15) | 1/24* (4.2) | 1/31* (3.2) | 5/61* (8.2) | 4/51* (7.8) |
| Chemoresistant relapse† | 26/37* (70.3) | 14/20* (70) | 4/24* (16.7) | 7/31* (22.6) | 30/61* (49.2) | 21/51* (41.2) |
| Graft composition (mean ± SD) | ||||||
| CD34+ × 106/kg | 14.7 ± 5* | 13.7 ± 4* | 16.7 ± 7* | 15.8 ± 6* | 15.9 ± 7* | 15.3 ± 4* |
| CD3+ × 104/kg | 5 ± 3.5* | 4.5 ± 4* | 3 ± 3.6* | 3.5 ± 3* | 3.5 ± 2* | 3.8 ± 3* |
| NK cell alloreactivity in GvH direction . | 1993–20014 . | 2002–2006 . | 1993–2006 . | |||
|---|---|---|---|---|---|---|
| No n = 37 . | Yes n = 20 . | No n = 24 . | Yes n = 31 . | No n = 61 . | Yes n = 51 . | |
| Status of disease at transplantation, n (%) | ||||||
| Bad-risk first and second CR | 7/37* (18.9) | 3/20* (15) | 19/24* (79.1) | 23/31* (74.2) | 26/61* (42.6) | 26/51* (51) |
| Myelodysplasia | 2/7 (28.6) | 1/3 (33.3) | 2/19 (10.5) | 5/23 (21.7) | 4/26 (15.5) | 6/26 (23) |
| Unfavorable cytogenetics | 2/7 (28.6) | 0/3 (0) | 4/19 (21.1) | 10/23 (43.5) | 6/26 (23) | 10/26 (38.5) |
| First-line induction therapy or autologous transplant failure | 3/7 (42.8) | 2/3 (66.7) | 13/19 (68.4) | 8/23 (34.8) | 16/26 (61.5) | 10/26 (38.5) |
| More than second complete remission | 4/37* (10.8) | 3/20* (15) | 1/24* (4.2) | 1/31* (3.2) | 5/61* (8.2) | 4/51* (7.8) |
| Chemoresistant relapse† | 26/37* (70.3) | 14/20* (70) | 4/24* (16.7) | 7/31* (22.6) | 30/61* (49.2) | 21/51* (41.2) |
| Graft composition (mean ± SD) | ||||||
| CD34+ × 106/kg | 14.7 ± 5* | 13.7 ± 4* | 16.7 ± 7* | 15.8 ± 6* | 15.9 ± 7* | 15.3 ± 4* |
| CD3+ × 104/kg | 5 ± 3.5* | 4.5 ± 4* | 3 ± 3.6* | 3.5 ± 3* | 3.5 ± 2* | 3.8 ± 3* |
*P = NS.
†Morphologic evidence of leukemic cells in the bone marrow and or blood after treatment.